Exact Mass: 320.1637

Exact Mass Matches: 320.1637

Found 15 metabolites which its exact mass value is equals to given mass value 320.1637, within given mass tolerance error 4.0E-5 dalton. Try search metabolite list with more accurate mass tolerance error 8.0E-6 dalton.

2-(4-(Piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide

2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide

C19H20N4O (320.1637)


D000970 - Antineoplastic Agents > D000067856 - Poly(ADP-ribose) Polymerase Inhibitors D004791 - Enzyme Inhibitors

   

MMV687706

MMV687706

C19H20N4O (320.1637)


   

2-(4-benzylpiperazin-1-yl)-1H-quinazolin-4-one

2-(4-benzylpiperazin-1-yl)-1H-quinazolin-4-one

C19H20N4O (320.1637)


   

6-(7-methyl-4-piperazin-1-yl-1H-quinazolin-2-ylidene)cyclohexa-2,4-dien-1-one

6-(7-methyl-4-piperazin-1-yl-1H-quinazolin-2-ylidene)cyclohexa-2,4-dien-1-one

C19H20N4O (320.1637)


   

(E)-3-[2-(Pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-amine

(E)-3-[2-(Pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-amine

C19H20N4O (320.1637)


   

Niraparib

MK-4827(Niraparib)

C19H20N4O (320.1637)


L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XK - Poly (adp-ribose) polymerase (parp) inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C62554 - Poly (ADP-Ribose) Polymerase Inhibitor D000970 - Antineoplastic Agents > D000067856 - Poly(ADP-ribose) Polymerase Inhibitors D004791 - Enzyme Inhibitors C471 - Enzyme Inhibitor

   

Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-

Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-

C19H20N4O (320.1637)


   

(R)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide

(R)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide

C19H20N4O (320.1637)


   

(Z)-2-cyano-3-(7-methyl-2-piperidin-1-ylquinolin-3-yl)prop-2-enamide

(Z)-2-cyano-3-(7-methyl-2-piperidin-1-ylquinolin-3-yl)prop-2-enamide

C19H20N4O (320.1637)


   

3-(6-Aminopyridin-3-YL)-N-methyl-N-[(1-methyl-1H-indol-2-YL)methyl]acrylamide

3-(6-Aminopyridin-3-YL)-N-methyl-N-[(1-methyl-1H-indol-2-YL)methyl]acrylamide

C19H20N4O (320.1637)


   

1-[5-(4-phenoxyphenyl)-1H-pyrazol-3-yl]piperazine

1-[5-(4-phenoxyphenyl)-1H-pyrazol-3-yl]piperazine

C19H20N4O (320.1637)


   

N-[2-(2-pyridinyl)-3H-benzimidazol-5-yl]cyclohexanecarboxamide

N-[2-(2-pyridinyl)-3H-benzimidazol-5-yl]cyclohexanecarboxamide

C19H20N4O (320.1637)


   

cyclopropyl-[(1S,5R)-7-[4-(5-pyrimidinyl)phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]methanone

cyclopropyl-[(1S,5R)-7-[4-(5-pyrimidinyl)phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]methanone

C19H20N4O (320.1637)


   

2-(4-(Piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide

2-(4-(Piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide

C19H20N4O (320.1637)


D000970 - Antineoplastic Agents > D000067856 - Poly(ADP-ribose) Polymerase Inhibitors D004791 - Enzyme Inhibitors

   

ABT-107

ABT-107

C19H20N4O (320.1637)


ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions[1][2].